MedTrace Logo

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

NCT00546728 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-11-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effects of exenatide versus metformin on vascular health with chronic (3-month) therapy and during a 2-hour period following a meal in patients with pre-diabetes. It is predicted that exenatide will improve vascular health to a greater degree compared to metformin.

Conditions

  • Impaired Glucose Tolerance

Interventions

DRUG

Exenatide

exenatide 10 mcg twice daily

DRUG

Metformin

metformin 500 twice daily

Sponsors & Collaborators

  • Amylin Pharmaceuticals, LLC.

    collaborator INDUSTRY

  • Eli Lilly and Company

    collaborator INDUSTRY

  • International Diabetes Center at Park Nicollet

    collaborator OTHER

  • St. Paul Heart Clinic

    lead OTHER

Principal Investigators

  • Aaron S. Kelly, Ph.D. · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546728 on ClinicalTrials.gov